Senti Biosciences Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
16.1%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$1.05next fiscal year
Monitoring Framework
Key Performance Indicators
SENTI-202 Composite Complete Remission (cCR) Rate (Donor X) Quarterly50.0%Target: Maximize complete remission rates in pivotal trial
Cash and Cash Equivalents Quarterly8.9MTarget: Secure additional tranches of Celadon convertible notes to extend runway
Watch Items
- Pivotal Single-Arm Trial Initiation for SENTI-202Trigger: FDA clearance of clinical protocol and CMC strategyAction: Initiate multi-center trial enrollment using Donor X phenotype
- Going Concern and Liquidity PressureTrigger: Cash runway falling below 1 quarter of operating expensesAction: Draw down on the remaining $30 million of the $40 million Celadon convertible note facility
Research as of 20 Jun 2026